Oracea (Doxycycline Monohydrate) Patent Expiration, LOE Window & CMS Spending

Oracea (Doxycycline Monohydrate) by Galderma Laboratories: FDA Orange Book LOE 2027-12-19, 13 AB generics, $3.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGalderma Laboratories
FDA Application & PathwayN050805 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2027-12-19
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors13
2024 CMS Total Public Spend$3.3M
2024 Medicare Part D Spend$3.2M
2024 Medicaid Spend$11K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel